Learn more about how AARSOTA Bio-Immunotherapy integrates with Hope4Cancer's non-toxic cancer treatment strategies. Hope4Cancer's alternative cancer treatments reduces the toxic effects of prior chemo and radiation treatments while directly healing the cancer.

1. AARSOTA BIO-IMMUNOTHERAPY
© Hope4Cancer Institute, All Rights Reserved

2. AARSOTA BIOIMMUNOTHERAPY
Antigen vs. Tumor Antigen
An antigen is a toxin or other foreign substance that
induces an immune response in the body, especially
the production of antibodies.
A tumor antigen is an antigenic substance produced
in tumor cells that can trigger an immune response
in the host. They are classified based on their
molecular structure and source, e.g., they could arise
from mutated oncogenes or tumor suppressor genes,
over-expressed or aberrantly expressed proteins,
oncogenic viruses etc.
© Hope4Cancer Institute, All Rights Reserved

3. AARSOTA BIOIMMUNOTHERAPY
Leveraging Tumor Antigens
Tumor Markers: The overexpression of certain
antigens makes them easy to associate with cancer
types. That is why detection of tumor markers is an
important diagnostic element in identifying and tracking
the progress of cancer.
Examples include CA 15-3 and CA 27.29 (breast
cancer), CA125 (ovarian cancer), CEA (colon cancer
and others), CA 19-9 (gastrointestinal and pancreatic
cancers), AFP (germ cell tumors and hepatocellular
carcinoma).
© Hope4Cancer Institute, All Rights Reserved

4. AARSOTA BIOIMMUNOTHERAPY
Leveraging Tumor Antigens
Therapeutic Cancer Vaccines: While vaccines are
typically designed for disease prevention, the
stimulation of the immune system to attack a disease
already present in the body can be accomplished with
a therapeutic cancer vaccine.
© Hope4Cancer Institute, All Rights Reserved

5. AARSOTA BIOIMMUNOTHERAPY
Methods to Activate Immune System
There are two distinct approaches to activate the
immune system using therapeutic cancer vaccines:
1. Immunize patients with tumor antigens sourced
from the tumor cells. These vaccines can be
directed to specific antigens, or the treatment can
be more generalized.
2. Generate a vaccine response in situ using
oncolytic viruses that stimulate the immune system
against the cancer in addition to replicating in and
causing the lysis of cancer cells.
© Hope4Cancer Institute, All Rights Reserved

6. AARSOTA BIOIMMUNOTHERAPY
Specific Antigen Vaccines in Development
• Aduro (GVAX), formerly being developed by Cell Genesys
• Advaxis (ADXS11-001, ADXS31-001, ADXS31-164)
• ALVAC-CEA vaccine
• AC Vaccine - Avax Technologies
• Biovax ID (Phase III): Accentia Biopharmaceuticals majority owned subsidiary Biovest International
• ProstVac - Bavarian Nordic
• Celldex Therapeutics (CDX110, CDX1307 and CDX1401)
• CimaVax-EGF - The Center of Molecular Immunology, Cuba (lung cancer)
• CV9104 – Cure Vac (castration-resistant prostate cancer)
• Neuvenge - Dendreon Corp (HER2/neu expressing cancers such as Breast, Bladder, Colon, Ovarian)
• Neuvax - Galena Biopharma
• Ae-37 - Generex Biotechnology / Antigen Express
• GRNVAC1 - Geron Corporation
• MAGE-A3 - GlaxoSmithKline (melanoma)
• Tarmogens, GI-4000, GI-6207, GI-6301 – GlobeImmune
• ImPACT - Heat Biologics against NSCLC and other cancers
• IMA901 - Immatics Biotechnologies
• Stimuvax – Oncothyreon – Failed at phase III for breast cancer.
• Peptide Vaccines - Oncotherapy Science (many candidates in advanced phase II trials)
• Cvac - Prima BioMed LTD (Ovarian Cancer – Phase III)
© Hope4Cancer Institute, All Rights Reserved

7. AARSOTA BIOIMMUNOTHERAPY
Specific vs. Whole Tumor Vaccines
CANCER
CELL
Therapeutic vaccines that use
specific antigens or their
fragments to elicit a targeted
immune response
Therapeutic vaccines created
with whole tumor cell
preparations that promise to
induce a wider immune response
“Whole tumor cells are a good source of TAAs and can induce
simultaneous CTLs and CD4(+) T helper cell activation.”
- Chiang, Benencia & Coukos. Whole Tumor Antigen Vaccines.
Semin. Immunol. 2010, 22, 132-43.
© Hope4Cancer Institute, All Rights Reserved

8. AARSOTA BIOIMMUNOTHERAPY
Big Limitations of Specific Antigen Vaccines
A tumor presents a large number of antigens, and
targeting any one antigen may not produce the
expected results.
Antigens are connected genetically to
the parent tumor cell. A Broad Institute
(Harvard & MIT) study has shown
that an individual can harbor
cancer cells equipped with different
mutations within the same tumor*.
* Lohr JG et al. “Widespread Genetic Heterogeneity in Multiple Myeloma:
Implications for Targeted Therapy.” Cancer Cell. DOI: 10.1016/ j.ccr.2013.12.015
© Hope4Cancer Institute, All Rights Reserved

9. AARSOTA BIOIMMUNOTHERAPY
AARSOTA: Using Antigens Effectively
* Lohr JG et al. “Widespread Genetic Heterogeneity in Multiple Myeloma:
Implications for Targeted Therapy.” Cancer Cell. DOI: 10.1016/ j.ccr.2013.12.015
CANCER
ANTIGEN
S
ASCITES
BLOOD
URINE
PROPRIETARY
SERUM
CONCETRATION
ANTIGEN
SERUM
© Hope4Cancer Institute, All Rights Reserved

10. AARSOTA BIOIMMUNOTHERAPY
What Is AARSOTA?
AARSOTA is obtained through the concentration of
large batches of fluids (urine or ascites) through a
proprietary process that enhances the the content of
cancer antigens to levels significant enough to
elicit an immune response.
The isolated serum is re-injected into the patient’s
blood stream to drive the immune response to
biologically relevant levels.
© Hope4Cancer Institute, All Rights Reserved

11. AARSOTA BIOIMMUNOTHERAPY
Advantages of AARSOTA
AARSOTA delivers a combination of all antigens from tumor
cells in the patient’s body, not just one specific antigen. The
resulting non-specific immune response has a better opportunity
to target the cancer.
Even for the same antigen type, AARSOTA is able to sample the
antigens produced from the genetically diverse pool of tumor
cells.
Even though the antigens are not identified, they are specific to
the tumor in the patient’s body, thereby tailoring the immune
response to the patient.
Since the antigens are obtained from the patient, the chances of
powerful, life-threatening immune reactions are unlikely.
© Hope4Cancer Institute, All Rights Reserved

12. AARSOTA BIOIMMUNOTHERAPY
Potential Drawback of AARSOTA
Since AARSOTA is made from the body fluids of the patient, the
success of the therapy is dependent on the quantity of
antigens released in the body fluid. It is not possible to tell
exactly if the antigenic concentration is sufficient to elicit a
relevant immune response.
© Hope4Cancer Institute, All Rights Reserved

13. AARSOTA BIOIMMUNOTHERAPY
The AARSOTA Protocol
To overcome AARSOTA’s biggest drawback, we implement the
following in any protocol that includes it as a treatment:
1. Combination Therapy: We combine AARSOTA with other
cancer-fighting treatments such as Sono-Photo Dynamic Therapy
and Hyperthermia, besides other immune enhancing therapies
and supplements. This is done in adherence to the Seven Key
Principles of Cancer Therapy.
2. Multiple Treatments: We recommend that patients repeat the
AARSOTA protocol every 2-3 months to maximize the benefits
and account for any genetic evolution of the tumor.
© Hope4Cancer Institute, All Rights Reserved

14. To learn more about Hope4Cancer’s Holistic Treatment
Protocols and Powerful, Non-Toxic Protocols contact
us at:
1-888-544-5993
+1-619-669-6511
Email: info@hope4cancer.com
www.hope4cancer.com
© Hope4Cancer Institute, All Rights Reserved